Table 1.
Baseline patient characteristics and medication use.
| Patients with worsening renal function (n=58) | Patients without worsening renal function (n=87) | p value | |
|---|---|---|---|
| Age | 59 ±14 | 56 ±14 | ns |
| NYHA class III/IV (%) | 9/91 | 10/90 | ns |
| Ischemic Etiology (%) | 54 | 50 | ns |
| Body mass index (kg/m2) | 28 ±3 | 29 ±4 | ns |
| Male Gender (%) | 74 | 73 | ns |
| Caucasian Race (%) | 78 | 76 | ns |
| Medical history (%) | |||
| Smoking history | 49 | 51 | ns |
| Diabetes | 44 | 34 | ns |
| Hypertension | 48 | 40 | ns |
| Hyperlipidemia | 60 | 59 | ns |
| ICD/CRT-D | 38/29 | 42/27 | ns |
| Labs on admission | |||
| Hemoglobin (g/dl) | 11.5 ±.2.5 | 13.0 ±1.5 | 0.05 |
| Creatinine (mg/dl) | 1.9 ±0.9 | 1.5 ±0.8 | 0.007 |
| GFR (ml/min/1.73.m2) | 48 ±19 | 56 ±25 | 0.05 |
| BUN (mg/dl) | 58 ±25 | 36 ±20 | <0.001 |
| Sodium (mmol/l) | 134 ±6 | 134 ±5 | ns |
| BNP (pg/ml) | 1,559 ±1340 | 1,157 ±1073 | ns |
| Oral Medication on Admission (%) | |||
| Aspirin/coumadin | 44 | 48 | ns |
| ACE-inhibitor/ARB | 49 | 50 | ns |
| Digoxin | 38 | 43 | ns |
| Beta-blockers | 56 | 62 | ns |
| Spironolactone | 27 | 47 | 0.03 |
| Loop diuretics | 80 | 86 | ns |
| Hydralazine | 23 | 17 | ns |
| Isosorbide dinitrate | 27 | 22 | ns |
| Statin | 57 | 54 | ns |
| Amiodarone | 22 | 19 | ns |
| Medication During PAC-Guided Therapy (%) | |||
| IV or PO furosemide | 85 | 86 | ns |
| IV vasodilators | 51 | 56 | ns |
| Milrinone | 34 | 30 | ns |
| Dobutamine | 30 | 27 | ns |
NYHA indicates New York Heart Association functional class, ICD: implantable cardiac defibrillator, CRT-D: cardiac resynchronization therapy with defibrillator, GFR: estimated glomerular filtration rate, BUN: blood urea nitrogen, ACE: angiotensin converting enzyme, ARB: angiotensin receptor blocker. Values are mean ± SD or n (%).